Cite
HARVARD Citation
Ferrante, M. et al. (n.d.). S809 A Higher Induction Dosing Regimen of Adalimumab Does Not Enhance Modulation of Downstream Blood Molecular Markers in Patients With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis. American journal of gastroenterology. p. S376. [Online].